Sanofi US News

Flu vaccine based on new technology within U.S. Government Preparedness Program

Shipment of Fluzone Influenza Virus Vaccine to U.S. Market Begins

Expands PLAVIX Indication to include patients with any acute coronary syndromes (ACS)

12 Million Men in U.S. at Risk for this Fragile Bone Disease

Results extending the role of AMBIEN CR in the treatment of insomnia presented at the 2006 CINP (Collegium Internationale Neuro-Psychopharmacologicum) 25th Biennial Congress

Complications from DVT kill up to 200,000 Americans every year, yet the risk of DVT can be reduced

Thrombosis Management Clinical Effectiveness Initiative(R) (CEI) Study Demonstrates Cost Savings of More Than $1,000 Per Discharge With Enoxaparin

Type 2 Diabetes Patients Using a New Insulin Dosing Strategy Achieved a Mean A1C of 6.6% after 24 Weeks of Combination Therapy with Rapid-Acting Apidra(R)

Findings show demonstrated overall survival with less febrile neutropenia for Taxotere(R) versus vinca-alkaloid regimens

430 abstracts from studies involving Taxotere(R) or Eloxatin(R) accepted at the meeting's scientific sessions

S-A Continues to Advocate for Solutions to Assist Patients Inside the Medicare Part D Benefit - Takes Steps to Ensure Patient Safety

Adam West and his wife team up to raise awareness of enlarged prostate due to BPH, the most common prostate problem in men

TAXOTERE(R)-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer

Certain subgroups may benefit from dual therapy, for others it should be avoided

New prandial insulin with the OptiClik(R) delivery system can work with longer-acting insulins, such as basal insulin Lantus(R), providing a complementary approach to glucose control

Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS(1); Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%

Study Shows Rimonabant Maintains Improvements in Multiple Cardiometabolic Risk Factors for Up to Two Years

New investigational doses include formulation with an adjuvant; Additional stockpile vaccine prepared

Filing for STEMI Indication Also Submitted in Europe

Lawsuit Alleges Advertising for Once-a-Month Osteoporosis Drug Misleads Physicians and Consumers